Trial Outcomes & Findings for A Study for Participants With Major Depression (NCT NCT00420004)

NCT ID: NCT00420004

Last Updated: 2018-04-27

Results Overview

The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

469 participants

Primary outcome timeframe

Baseline, Week 8

Results posted on

2018-04-27

Participant Flow

A total of 701 participants were included in a screening/washout period (from 3 to 30 days in duration) prior to group assignments; 232 participants discontinued during this period, and 469 participants were randomized. There was an 8-week Double-blind Phase followed by a 1-week Discontinuation Phase after abrupt discontinuation of treatment.

Participant milestones

Participant milestones
Measure
LY2216684
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Overall Study
STARTED
269
138
62
Overall Study
Received at Least 1 Dose of Study Drug
249
122
54
Overall Study
COMPLETED
140
67
30
Overall Study
NOT COMPLETED
129
71
32

Reasons for withdrawal

Reasons for withdrawal
Measure
LY2216684
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Overall Study
Adverse Event
4
1
1
Overall Study
Lack of Efficacy
5
4
1
Overall Study
Lost to Follow-up
31
12
10
Overall Study
Entry Criteria Not Met
0
1
0
Overall Study
Physician Decision
14
4
2
Overall Study
Protocol Violation
5
4
3
Overall Study
Withdrawal by Subject
67
42
14
Overall Study
Sponsor Decision
3
3
1

Baseline Characteristics

A Study for Participants With Major Depression

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
LY2216684
n=269 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=138 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=62 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Total
n=469 Participants
Total of all reporting groups
Age, Continuous
36.64 years
STANDARD_DEVIATION 10.21 • n=99 Participants
37.54 years
STANDARD_DEVIATION 10.97 • n=107 Participants
34.32 years
STANDARD_DEVIATION 9.66 • n=206 Participants
36.60 years
STANDARD_DEVIATION 10.40 • n=7 Participants
Sex: Female, Male
Female
130 Participants
n=99 Participants
65 Participants
n=107 Participants
22 Participants
n=206 Participants
217 Participants
n=7 Participants
Sex: Female, Male
Male
139 Participants
n=99 Participants
73 Participants
n=107 Participants
40 Participants
n=206 Participants
252 Participants
n=7 Participants
Race/Ethnicity, Customized
Caucasian
30 Participants
n=99 Participants
21 Participants
n=107 Participants
8 Participants
n=206 Participants
59 Participants
n=7 Participants
Race/Ethnicity, Customized
African
6 Participants
n=99 Participants
5 Participants
n=107 Participants
0 Participants
n=206 Participants
11 Participants
n=7 Participants
Race/Ethnicity, Customized
Hispanic
23 Participants
n=99 Participants
7 Participants
n=107 Participants
4 Participants
n=206 Participants
34 Participants
n=7 Participants
Race/Ethnicity, Customized
Native American
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race/Ethnicity, Customized
West Asian (Indian subcontinent)
209 Participants
n=99 Participants
105 Participants
n=107 Participants
50 Participants
n=206 Participants
364 Participants
n=7 Participants
Region of Enrollment
United States
39 Participants
n=99 Participants
23 Participants
n=107 Participants
8 Participants
n=206 Participants
70 Participants
n=7 Participants
Region of Enrollment
Romania
7 Participants
n=99 Participants
4 Participants
n=107 Participants
1 Participants
n=206 Participants
12 Participants
n=7 Participants
Region of Enrollment
India
208 Participants
n=99 Participants
105 Participants
n=107 Participants
50 Participants
n=206 Participants
363 Participants
n=7 Participants
Region of Enrollment
Mexico
15 Participants
n=99 Participants
6 Participants
n=107 Participants
3 Participants
n=206 Participants
24 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline, Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-17 value.

The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Outcome measures

Outcome measures
Measure
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
-13.2 units on a scale
Standard Error 0.53
-12.6 units on a scale
Standard Error 0.74
-14.7 units on a scale
Standard Error 1.14

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Maier-Philipp subscale value.

The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The Maier-Phillip subscale of the HAMD-17 represents the 6 "core" symptoms of depression (items: 1=depressed mood, 2=feelings of guilt, 7=work and activities, 8=retardation, 9=agitation, 10=anxiety/psychic). The subscale scores range from 0 (normal) to 24 (severe). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Outcome measures

Outcome measures
Measure
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline to Week 8 in Maier-Philipp Subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17)
-6.7 units on a scale
Standard Error 0.26
-6.2 units on a scale
Standard Error 0.36
-7.6 units on a scale
Standard Error 0.55

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-17 total score value. Last observation carried forward (LOCF) methodology was used.

A participant meets response criteria if there is at least a 50% reduction in the 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the last observation carried forward (LOCF) endpoint visit. A participant meets remission criteria if the HAMD-17 total score is less than or equal to 7 at the LOCF endpoint visit. The percent of participants meeting criteria is summarized. HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed).

Outcome measures

Outcome measures
Measure
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Response and Remission Rates
Remission
38.7 percentage of participants
31.1 percentage of participants
42.6 percentage of participants
Response and Remission Rates
Response
54.0 percentage of participants
48.4 percentage of participants
53.7 percentage of participants

SECONDARY outcome

Timeframe: Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline CGI-I value.

The Clinical Global Impression of Improvement (CGI-I) scale measures the clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much improved) to 7 (very much worse). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, and treatment-by-visit.

Outcome measures

Outcome measures
Measure
LY2216684
n=247 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=53 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Clinical Global Impression of Improvement Score at Week 8
2.2 units on a scale
Standard Error 0.09
2.3 units on a scale
Standard Error 0.12
2.0 units on a scale
Standard Error 0.19

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMA value. Last observation carried forward (LOCF) methodology was used.

The HAMA is a 14-item assessment used to assess the severity of anxiety. The investigator talked to the participant about the symptoms he or she experienced during the previous week. Each item was scored using a 5-point scale (0=not present to 4=very severe). The total score of HAMA ranged from 0 (normal) to 56 (severe). Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=212 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=106 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=44 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Hamilton Anxiety Rating Scale (HAMA) Total Score up to Week 8 Endpoint
-9.7 units on a scale
Standard Error 0.62
-9.6 units on a scale
Standard Error 0.82
-11.6 units on a scale
Standard Error 1.19

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline SF-36 Health Status Survey value. Last observation carried forward (LOCF) methodology was used.

The SF-36 Health Status Survey is a generic, health-related scale assessing a participant's quality of life on 8 domains: general health (GH), physical functioning (PF), role-physical, role-emotional, social functioning, bodily pain, vitality, and mental health. Each domain is scored by summing the individual items (GH \[range: 5-25\]; PF \[range: 10-30\]; role-physical \[range: 4-8\]; role-emotional \[range: 3-6\]; social functioning \[range: 2-10\]; bodily pain \[range: 2-11\]; vitality \[range: 4-24\]; mental health \[range: 5-30\]) and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores (mental component and physical component scores) were constructed based on the 8 SF-36 domains. Mental component summary and physical component summary scores range from 0 to 100 (higher scores indicate better health status).

Outcome measures

Outcome measures
Measure
LY2216684
n=192 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=99 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=41 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline on the 36-item Short-Form (SF-36) Health Status Survey Mental and Physical Components up to Week 8 Endpoint
Mental Component Summary
13.4 units on a scale
Standard Deviation 13.1
12.6 units on a scale
Standard Deviation 13.9
12.4 units on a scale
Standard Deviation 12.4
Change From Baseline on the 36-item Short-Form (SF-36) Health Status Survey Mental and Physical Components up to Week 8 Endpoint
Physical Component Summary
4.17 units on a scale
Standard Deviation 9.00
2.37 units on a scale
Standard Deviation 8.26
2.74 units on a scale
Standard Deviation 7.65

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Quick Inventory of Depressive Symptomatology value. Last observation carried forward (LOCF) methodology was used.

The Quick Inventory of Depressive Symptomatology is a 16-item participant-rated measure of depressive symptomatology. There were 4 possible answers per question that are specific to the question; each question (Q) was scored 0 (no problems) to 3 (increased symptoms). The total score was the sum of the highest number from Q1-4, number from Q5, highest number from Q6-9, total for Q10-14, and the highest number from Q15-16. The total score ranges from 0 to 27 with higher scores indicative of greater severity of depression. Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=198 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=103 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=42 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Quick Inventory of Depressive Symptomatology Total Score up to Week 8 Endpoint
-10.2 units on a scale
Standard Error 0.54
-8.3 units on a scale
Standard Error 0.71
-11.6 units on a scale
Standard Error 1.04

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline BSI value. Last observation carried forward (LOCF) methodology was used.

Beck Scale for Suicide Ideation (BSI) is a 21-item participant-completed questionnaire designed to assess severity of suicidal ideation in adults and adolescents. The BSI total score is calculated as the sum of the responses (rated from 0 to 2 in terms of severity) to the first 19 items of the BSI scale. The BSI total score ranges from 0 to 38, with a higher score indicating a higher degree of suicide ideation.

Outcome measures

Outcome measures
Measure
LY2216684
n=245 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=51 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Beck Scale for Suicide Ideation up to Week 8 Endpoint
-0.90 units on a scale
Standard Deviation 3.39
-0.54 units on a scale
Standard Deviation 2.14
-0.78 units on a scale
Standard Deviation 2.16

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline OAS-M value. Last observation carried forward (LOCF) methodology was used.

OAS-M is a clinician-administered semistructured interview designed to assess various manifestations of aggressive behavior. Final scores are rated on 3 scales: Aggression (Agg), Irritability (Irrt), Suicidality (Suic). Agg scale has 4 subscales: Verbal Assault (Aslt), Aslt Against Objects, Aslt Against Others, Aslt Against Self; each item is scored 0-5, multiplied by the frequency of the behavior, then summed together. Agg total score is the weighted sum of the subscale scores (weights: 1=Verbal Aslt, 2=Aslt Against Objects, 3=Aslt Against Others, 4=Aslt Against Self). The Irrt scale has 2 subscales: Global Irrt, Subjective Irrt. Suic scale has 3 subscales: Suicidal Tendencies, Intent of Attempt, Lethality of Attempt. The 2 Irrt and 3 Suic subscales are rated on 6 or 7 point scales from 0=none/not at all to 6/7=very extreme. The total score ranges from 0-10 for the Irrt scale and 0-16 on the Suic scale. Least Squares means were adjusted for treatment, investigator, and baseline s

Outcome measures

Outcome measures
Measure
LY2216684
n=227 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=113 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=47 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Irritability total score
-1.0 units on a scale
Standard Error 0.10
-0.9 units on a scale
Standard Error 0.14
-1.0 units on a scale
Standard Error 0.20
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Aggression total score
-4.1 units on a scale
Standard Error 0.52
-4.2 units on a scale
Standard Error 0.71
-3.9 units on a scale
Standard Error 1.06
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Suicidality total score
-0.2 units on a scale
Standard Error 0.04
-0.2 units on a scale
Standard Error 0.05
-0.2 units on a scale
Standard Error 0.08

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline ASEX value. Last observation carried forward (LOCF) methodology was used.

The Arizona Sexual Experiences Scale (ASEX) is used to assess sexual functioning in both males and females. The ASEX total score for the male and female version is calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) to the 5 items of the ASEX scale. Total scores ranged from 5 to 30 with higher scores indicating greater sexual dysfunction.

Outcome measures

Outcome measures
Measure
LY2216684
n=219 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=109 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Arizona Sexual Experiences Scale up to Week 8 Endpoint
-2.68 units on a scale
Standard Deviation 6.65
-1.69 units on a scale
Standard Deviation 6.35
-1.65 units on a scale
Standard Deviation 7.43

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline ISI value. Last observation carried forward (LOCF) methodology was used.

The Insomnia Severity Index (ISI) is a brief self-report instrument measuring the participant's perception of his or her insomnia. The ISI score is calculated as the sum of the responses to the 7 items of the ISI scale. Each item is rated on a 0 to 4 scale and the total score ranges from 0 to 28 with a higher score suggesting more severe insomnia.

Outcome measures

Outcome measures
Measure
LY2216684
n=227 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=113 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=45 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline in Insomnia Severity Index up to Week 8 Endpoint
-7.53 units on a scale
Standard Deviation 7.57
-7.44 units on a scale
Standard Deviation 7.73
-8.02 units on a scale
Standard Deviation 7.72

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline FSS value.

Fatigue Severity Scale (FSS) is a 9-item measure of fatigue severity. Each item is scored by the participant on a scale of 1 ("Disagree") to 7 ("Agree"), with a higher score indicating a stronger agreement with the item statement regarding the participant's fatigue symptoms. The FSS total score ranges from 1 to 7, and is obtained by averaging the responses to the 9 items. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Outcome measures

Outcome measures
Measure
LY2216684
n=225 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=109 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=47 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline to Week 8 in Fatigue Severity Scale
-2.0 units on a scale
Standard Error 0.14
-1.8 units on a scale
Standard Error 0.19
-2.2 units on a scale
Standard Error 0.29

SECONDARY outcome

Timeframe: Up to 8 weeks

Population: All participants randomized to LY2216684 included in the primary efficacy analysis with a pharmacokinetic (PK) sample at the participants' final study visit.

Predicted maximal LY2216684 plasma concentrations at steady state (Cmax,ss) are reported, using the dose at the last visit in the study for participants included in the primary efficacy analysis.

Outcome measures

Outcome measures
Measure
LY2216684
n=193 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
3 mg dose
10.5 nanograms per milliliter (ng/mL)
Standard Deviation 2.0
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
6 mg dose
22.6 nanograms per milliliter (ng/mL)
Standard Deviation 5.4
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
9 mg dose
32 nanograms per milliliter (ng/mL)
Standard Deviation 6.4
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
12 mg dose
40.6 nanograms per milliliter (ng/mL)
Standard Deviation 9.9

SECONDARY outcome

Timeframe: Baseline through Week 8

Population: All randomized participants.

The number of participants with at least one serious adverse event, regardless of causality is reported cumulatively through Week 8. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.

Outcome measures

Outcome measures
Measure
LY2216684
n=269 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=138 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=62 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Number of Participants With at Least 1 Serious Adverse Event (Safety and Tolerability)
2 Participants
1 Participants
2 Participants

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-21 value.

The HAMD-21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 60 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.

Outcome measures

Outcome measures
Measure
LY2216684
n=239 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=120 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=52 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Change From Baseline to Week 8 in the 21-item Hamilton Depression Rating Scale (HAM-21) Total Score
-13.6 units on a scale
Standard Error 0.57
-13.0 units on a scale
Standard Error 0.79
-15.0 units on a scale
Standard Error 1.24

SECONDARY outcome

Timeframe: Baseline, up to week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who have a baseline and at least one post-baseline WLDRT value. Last observation carried forward (LOCF) methodology was used.

The WLDRT is a test of visual learning and recall. Participants are shown a series of words (commonly used nouns) and asked to say each of the words aloud, then are asked to recall the words and the total number of correct words recalled is recorded (possible score ranged from 0 to 15 words). The process is repeated 3 times. The Word List Learning Test score is calculated as the average number of words recalled during the first 3 trials. After a 30-minute delay, participants are again asked to recall the words, and the total number of correct words remembered after the delay is recorded as the Delayed Recall Test score. The baseline value was the last non-missing value before the first randomized double-blind study drug administration. Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=207 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=107 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Cognitive Assessment Battery: Change From Baseline in Word List Learning and Delayed Recall Test (WLDRT) up to Week 8 Endpoint
Word List Learning Test
0.5 number of correct words
Standard Error 0.15
0.3 number of correct words
Standard Error 0.19
0.3 number of correct words
Standard Error 0.28
Cognitive Assessment Battery: Change From Baseline in Word List Learning and Delayed Recall Test (WLDRT) up to Week 8 Endpoint
Delayed Recall Test
0.4 number of correct words
Standard Error 0.19
0.2 number of correct words
Standard Error 0.25
0.0 number of correct words
Standard Error 0.37

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline SDST value. Last observation carried forward (LOCF) methodology was used.

The SDST is an attention-demanding psychomotor component based on the Digit Symbol Substitution Test from the Wechsler Adult Intelligence Scale. The participant is given a symbol/digit code in which each of the digits 1 through 9 is paired with a different symbol. Below the code, a series of symbols selected from those in the code are presented in an irregular order. The participant is instructed to write the number that is appropriate for each symbol in the space below each symbol and to complete as many correct digits as possible within a 90-second test period. For this test, the number of attempts and number of correct digits is collected. The percentage of correct digits is presented based on the number of correct digits divided by the number of attempts, multiplied by 100 (score ranged from 0 to 100% correct). Least squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=182 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=94 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=39 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Cognitive Assessment Battery: Change From Baseline in Symbol Digit Substitution Test (SDST) up to Week 8 Endpoint
3.2 percentage of correct digits
Standard Error 1.12
2.5 percentage of correct digits
Standard Error 1.42
2.2 percentage of correct digits
Standard Error 2.10

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline 2DCT value. Last observation carried forward (LOCF) methodology was used.

The Two Digit Cancellation Test (2DCT) is a clinical adaptation of the visual search tasks that have been used to investigate cognitive processes involved in attention and visual information processing. For this test, the participant is presented with a piece of paper containing rows of digits. At the top of the page are two target digits. The participant is instructed to examine each row of digits working from top to bottom and left to right crossing off each number that matches either of the two numbers at the top of the page. The number of targets hit, number of errors, and number of times the participant had to be reminded of the task are recorded for the 45-second test. The 2DCT composite cognitive score is calculated as the number of targets hit - number of errors - number of reminders. 2DCT score ranges 0-40 with higher score indicating better cognition. Least squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=194 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=99 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=49 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Cognitive Assessment Battery: Change From Baseline in Two Digit Cancellation Test up to Week 8 Endpoint
0.8 units on a scale
Standard Error 0.62
1.2 units on a scale
Standard Error 0.83
1.0 units on a scale
Standard Error 1.26

SECONDARY outcome

Timeframe: Baseline, up to Week 8

Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Trail Making A value. Last observation carried forward (LOCF) methodology was used.

Trail Making A is a neurocognitive test associated with general brain function. While being timed, the participant is instructed to connect 25 randomly placed circled numbers on a page in numerical sequence without lifting their pencil. If a participant makes a mistake, the mistake is pointed out and the participant must start again from the last correct circle. The total time to complete the task (up to 300 seconds, with a lower value indicating better brain function) is recorded. Least squares (LS) means were adjusted for treatment, investigator, and baseline score.

Outcome measures

Outcome measures
Measure
LY2216684
n=203 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
Placebo
n=104 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
Cognitive Assessment Battery: Change From Baseline in Trail Making A up to Week 8 Endpoint
-9.9 seconds
Standard Error 2.97
-11.1 seconds
Standard Error 3.85
-5.6 seconds
Standard Error 5.68

Adverse Events

LY2216684 Double Blind Phase

Serious events: 2 serious events
Other events: 70 other events
Deaths: 0 deaths

Placebo Double Blind Phase

Serious events: 1 serious events
Other events: 26 other events
Deaths: 0 deaths

Escitalopram Double Blind Phase

Serious events: 2 serious events
Other events: 19 other events
Deaths: 0 deaths

LY2216684 Discontinuation Phase

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Placebo Discontinuation Phase

Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths

Escitalopram Discontinuation Phase

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
LY2216684 Double Blind Phase
n=269 participants at risk
LY2216684: 3, 6, 9, or 12 milligrams (mg) tablets, administered orally with flexible dosing, once daily for 8 weeks
Placebo Double Blind Phase
n=138 participants at risk
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally once daily for 8 weeks
Escitalopram Double Blind Phase
n=62 participants at risk
Escitalopram: 10 or 20 mg capsules, administered orally with flexible dosing, once daily for 8 weeks
LY2216684 Discontinuation Phase
n=269 participants at risk
Included all randomized participants who discontinued LY2216684 treatment
Placebo Discontinuation Phase
n=138 participants at risk
Included all randomized participants who discontinued placebo
Escitalopram Discontinuation Phase
n=62 participants at risk
Included all randomized participants who discontinued escitalopram treatment
Blood and lymphatic system disorders
Anaemia
0.37%
1/269 • Number of events 1
0.00%
0/138
0.00%
0/62
0.00%
0/269
0.00%
0/138
0.00%
0/62
Infections and infestations
Gastroenteritis
0.00%
0/269
0.72%
1/138 • Number of events 1
1.6%
1/62 • Number of events 1
0.00%
0/269
0.00%
0/138
0.00%
0/62
Infections and infestations
Malaria
0.00%
0/269
0.00%
0/138
1.6%
1/62 • Number of events 1
0.00%
0/269
0.00%
0/138
0.00%
0/62
Injury, poisoning and procedural complications
Near drowning
0.00%
0/269
0.00%
0/138
0.00%
0/62
0.00%
0/269
0.72%
1/138 • Number of events 1
0.00%
0/62
Psychiatric disorders
Depression
0.37%
1/269 • Number of events 1
0.00%
0/138
0.00%
0/62
0.00%
0/269
0.00%
0/138
0.00%
0/62
Psychiatric disorders
Suicide attempt
0.00%
0/269
0.00%
0/138
1.6%
1/62 • Number of events 1
0.00%
0/269
0.00%
0/138
0.00%
0/62

Other adverse events

Other adverse events
Measure
LY2216684 Double Blind Phase
n=269 participants at risk
LY2216684: 3, 6, 9, or 12 milligrams (mg) tablets, administered orally with flexible dosing, once daily for 8 weeks
Placebo Double Blind Phase
n=138 participants at risk
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally once daily for 8 weeks
Escitalopram Double Blind Phase
n=62 participants at risk
Escitalopram: 10 or 20 mg capsules, administered orally with flexible dosing, once daily for 8 weeks
LY2216684 Discontinuation Phase
n=269 participants at risk
Included all randomized participants who discontinued LY2216684 treatment
Placebo Discontinuation Phase
n=138 participants at risk
Included all randomized participants who discontinued placebo
Escitalopram Discontinuation Phase
n=62 participants at risk
Included all randomized participants who discontinued escitalopram treatment
Gastrointestinal disorders
Constipation
6.7%
18/269 • Number of events 19
5.1%
7/138 • Number of events 7
1.6%
1/62 • Number of events 1
0.00%
0/269
0.00%
0/138
0.00%
0/62
Gastrointestinal disorders
Dry mouth
6.3%
17/269 • Number of events 17
4.3%
6/138 • Number of events 6
6.5%
4/62 • Number of events 4
0.00%
0/269
0.72%
1/138 • Number of events 1
0.00%
0/62
Gastrointestinal disorders
Nausea
8.9%
24/269 • Number of events 27
3.6%
5/138 • Number of events 5
11.3%
7/62 • Number of events 7
0.00%
0/269
0.00%
0/138
1.6%
1/62 • Number of events 1
Nervous system disorders
Headache
9.7%
26/269 • Number of events 34
6.5%
9/138 • Number of events 9
11.3%
7/62 • Number of events 7
0.74%
2/269 • Number of events 2
0.72%
1/138 • Number of events 1
1.6%
1/62 • Number of events 1
Psychiatric disorders
Insomnia
5.2%
14/269 • Number of events 15
2.9%
4/138 • Number of events 4
3.2%
2/62 • Number of events 2
0.74%
2/269 • Number of events 2
0.00%
0/138
0.00%
0/62

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60